IL6R and acute respiratory distress syndrome: Worth mentioning are chloroquine and hydroxychloroquine to interfere with the viral entry and replication, anti-interleukin-6 receptor monoclonal antibodies (anti-IL-6R) for reducing the inflammatory response upon cytokine storm [21], and corticosteroids, previously used to treat SARS and MERS infections, and frequently administered to COVID-19 patients to reduce lung inflammation and prevent ARDS development [22].